Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter ending June 30, 2018. Jan D Alvise, p
REDWOOD CITY- AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,090,909 shares of AcelRx's common...
Acorda Therapeutics, Inc. today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acorda s Chief of Business Operations, will assume responsibility for the company s Chelsea, MA manufacturi
Guided by the novel endpoint development framework released by the Clinical Trials Transformation Initiative in 2017, ActiGraph's Scientific Affairs and Data Management division, headed by Director Tyler Guthrie, will facilitate joint research and development projects involving corporate partners and subject matter experts from within the...
But experts who pay close attention to federal drug policy and Medicare rules say the administration is preparing to incrementally roll out a multipronged plan that tasks the Centers for Medicare& Medicaid Services and the Food and Drug Administration with promoting competition, attacking the complicated drug rebate system and introducing tactics t
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018.. The Company reported a net loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, compared to a net loss of $1.7 million or $0.15 pe
-Adherium, a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie solution in the U.S., following its recent Food and Drug Administration 510 over-the-counter clearance to enable sales direct to consumers. Adherium believes health technology should be simple to use
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a business update. We had a busy and productive second quarter at Aerpio, commented Stephen Hoffman, M.D. Second, we completed an
CHARLESTON- Aeterna Zentaris Inc., a biopharmaceutical company engaged in developing and commercializing pharmaceutical products, today reported financial and operating results for the second quarter ended June 30, 2018. Aeterna Zentaris Inc. is a biopharmaceutical company focused on developing and commercializing, principally through...
Aevi Genomic Medicine, Inc. today announced that it has completed enrollment in Part A of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive genetic subset of pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder, to confirm response to AEVI-001 in these patients. "We are pleased that we hav
-AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, announced today that it has entered into a common stock purchase agreement and registration rights..
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced financial results for the fiscal first quarter ended June 30, 2018.
BOSTON- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Wedbush PacGrow Healthcare Conference at the Parker New York in New York City on Tuesday, August 14, 2018, at 8:35 a.m. ED
NEWTON- Allena Pharmaceuticals, Inc., a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena's President and Chief Operating Officer, will present a company...
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced the appointment of Susie Jun, M.D., Ph.D., as Chief Development Officer. Dr. Jun has also served as Senior Director, Hem/Onc Clinical Research, at Gilead, and as Executive Medical Director, Hematol
Amicus Therapeutics first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy. The oral drug is an alternative to the infused enzyme replacement therapy that is current standard of care Sanofi/ Genzymes Fabarazyme. Already approved in Europe,
The battle between Vertex Pharmaceuticals and U.K. health officials over cystic fibrosis drug pricing has reached an impasse after NHS Englands final offer in July. In a statement, Vertex director of external communications Heather Nichols said the company supports the need for robust and fair medicines appraisal in England. Vertex and U.K. health.
Analyst Ratings For Amneal Pharmaceuticals Inc (NYSE:AMRX) Today, Canaccord Genuity raised its price target on Amneal Pharmaceuticals Inc (NYSE:AMRX) to $21.00 per share. There are 4 Hold Ratings, 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Amneal Pharmaceuticals Inc (NYSE:AMRX) is Buy with a
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. This discussion should be read in conjunction with our historical financial statements. For additional information regarding these risks and uncertainties, please see Part II, Item 1 A of this Form 10- Q, "Risk Factors," and the risk factors included in our Annua
This management's discussion and analysis of the financial condition and results of operations of the Company should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes for the three and six months ended June 30, 2018 and 2017, which have been prepared in accordance with United States general
BAUDETTE- ANI Pharmaceuticals, Inc. ANIP, -1.74% today reported its financial results for the three and six months ended June 30, 2018 and updated its 2018 financial guidance. Arthur S. Przybyl, President and CEO, stated,' In the second quarter of 2018 ANI continued to successfully execute on its strategy to grow the brand and generic business plat
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results and business highlights for the second quarter ended June 30, 2018.. This was a transformational quarter for Aptinyx as we completed a successful IPO that provide
VANCOUVER- Aquinox Pharmaceuticals, Inc., a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the second quarter ending June 30, 2018. As a result, we've halted all development activities for rosipt
Our future financial condition, as well as any forward-looking statements are subject to significant risks and uncertainties including, but not limited to the factors set forth under the heading "Forward Looking Statements" and "Item 1 A. Risk Factors" under Part I of this Annual Report on Form 10- K, and in other reports we file with the SEC. Ther
Array BioPharma Inc. today reported results for its fourth quarter and full year of fiscal 2018 and provided an update on the progress of its key commercial products and clinical development programs. "We were thrilled to launch BRAFTOVI?+ MEKTOVI for patients with BRAF- mutant melanoma in the U.S. after receiving FDA approval for the combi